Pre-Treatment of Platinum Resistant Ovarian Cancer Cells with an MMP-9/MMP-2 Inhibitor Prior to Cisplatin Enhances Cytotoxicity as Determined by High Content Screening

Platinum resistance is a major cause of treatment failure in ovarian cancer. We previously identified matrix metalloproteinase 9 (MMP-9) as a potential therapeutic target of chemoresistant disease. A2780cis (cisplatin-resistant) and A2780 (cisplatin-sensitive) ovarian carcinoma cell lines were used....

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Laios, Alexandros, Mohamed, Bashir M., Kelly, Lynne, Flavin, Richard, Finn, Stephen, McEvoy, Lynda, Gallagher, Michael, Martin, Cara, Sheils, Orla, Ring, Martina, Davies, Anthony, Lawson, Margaret, Gleeson, Noreen, D’Arcy, Tom, d’Adhemar, Charles, Norris, Lucy, Langhe, Ream, Saadeh, Feras Abu, O’Leary, John J., O’Toole, Sharon A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: MDPI 2013
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3565367/
https://ncbi.nlm.nih.gov/pubmed/23340649
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms14012085
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak